REFERENCES
1. IRAC, Intermediate Agency for Research on Cancer. Epidemiology of HCC. Available from: https://www.iarc.fr [Last accessed on 1 Jan 2016].
2. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013;13:123-35.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
4. Guo X, Wang X. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009;19:71-88.
5. Bellam N, Pasche B. TGF-β signaling alterations and colon cancer. Cancer Treat Res 2010;155:85-103.
6. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 2005;106:756-63.
7. Teicher BA. Malignant cells, directors of malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133-43.
8. Mu-oz-Antonia T, Torrellas-Ruiz M, Clavell J, Mathews LA, Muro-Cacho CA, Bàez A. Aberrant methylation inactivates transforming growth factor beta receptor 1 in head and neck squamous cell carcinoma. Int J Otolrayngol 2009;2009:848695.
9. Lee D, Chung YH, Kim JA, Lee YS, Lee D, Jang MK, Kim KM, Lim YS, Lee HC, Lee YS. Transforming growth factor beta 1 over expression is closely related to invasiveness of hepatocellular carcinoma. Oncology 2012;82:11-8.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
11. Oh S, Kim E, Kang D, Kim M, Kim JH, Song JJ. Transforming growth factor-beta gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA. Cancer Gene Ther 2013;20:94-100.
12. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
13. Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor beta 1 in the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol 2013;30:673.
14. Pérez-Gómez E, Castillo G, Santibanez JF, López-Novoa JM, Bernabéu C, Quintanella M. The role of the TGF-β coreceptor endoglin in cancer. Sci World J 2010;10:2367-84.
15. Shariat SF, Kim JH, Andrew B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma level of transforming growth factor b strongly predict patients outcome in bladder carcinoma. Cancer 2001;92:2985-92.
16. Hussein M, Ibrahim AA, Khattab NF, El-Fouly RF, El-Fouly NF. Serum transforming growth factor beta 1 in hepatitis C virus related chronic liver disease and hepatocellular carcinoma patients. Med J Cairo Uni 2010;78:279-86.
17. Flisiak R, Prokopovicz D. Transforming growth factor beta 1 as a surrogate marker of hepatic dysfunction in chronic liver disease. Clin Chem Lab Med 2000;38:1129-31.
18. Mayoral R, Valverde MA, Izquirdo LC, Gonzàles-Rodríguez A, Boscà L, Martín-Sanz P. Impairment of transforming growth factor beta signaling in Caveolin-1 deficient hepatocytes: role in liver regeneration. J Biol Chem 2010;285:3633-42.
